Jump Financial LLC Sells 9,134 Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Jump Financial LLC lessened its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 19.5% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 37,634 shares of the company's stock after selling 9,134 shares during the quarter. Jump Financial LLC owned approximately 0.08% of Mirum Pharmaceuticals worth $1,556,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Jones Financial Companies Lllp lifted its position in Mirum Pharmaceuticals by 100.0% during the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after buying an additional 357 shares during the period. R Squared Ltd bought a new position in shares of Mirum Pharmaceuticals in the 4th quarter worth about $69,000. AlphaQuest LLC lifted its position in Mirum Pharmaceuticals by 969.6% during the 4th quarter. AlphaQuest LLC now owns 1,829 shares of the company's stock valued at $76,000 after acquiring an additional 1,658 shares during the period. Summit Investment Advisors Inc. boosted its stake in Mirum Pharmaceuticals by 8.1% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,155 shares of the company's stock worth $172,000 after acquiring an additional 312 shares in the last quarter. Finally, Avanza Fonder AB purchased a new stake in Mirum Pharmaceuticals in the fourth quarter worth about $189,000.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on MIRM. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. HC Wainwright increased their target price on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, February 28th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of "Buy" and a consensus price target of $58.20.

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals stock traded up $0.19 during midday trading on Wednesday, reaching $39.62. 524,598 shares of the company traded hands, compared to its average volume of 523,703. Mirum Pharmaceuticals, Inc. has a 12 month low of $23.14 and a 12 month high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. The business has a 50 day moving average of $44.76 and a two-hundred day moving average of $43.97. The firm has a market capitalization of $1.96 billion, a price-to-earnings ratio of -19.61 and a beta of 1.00.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.22). Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The firm had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. As a group, research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In related news, COO Peter Radovich sold 3,177 shares of the firm's stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $152,241.84. Following the transaction, the chief operating officer now owns 29,588 shares of the company's stock, valued at approximately $1,417,856.96. This trade represents a 9.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Patrick J. Heron bought 1,335 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, March 4th. The shares were acquired at an average cost of $45.57 per share, with a total value of $60,835.95. Following the completion of the acquisition, the director now owns 163,643 shares of the company's stock, valued at $7,457,211.51. The trade was a 0.82 % increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 116,473 shares of company stock worth $5,249,134 in the last three months. 22.87% of the stock is currently owned by company insiders.

Mirum Pharmaceuticals Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.